These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693 [TBL] [Abstract][Full Text] [Related]
23. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824 [TBL] [Abstract][Full Text] [Related]
24. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872 [TBL] [Abstract][Full Text] [Related]
25. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548 [TBL] [Abstract][Full Text] [Related]
26. [Next treatment for TKI-resistant CML]. Takahashi N Rinsho Ketsueki; 2023; 64(9):981-987. PubMed ID: 37793874 [TBL] [Abstract][Full Text] [Related]
27. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F Am J Physiol Cell Physiol; 2024 Jul; 327(1):C184-C192. PubMed ID: 38826137 [TBL] [Abstract][Full Text] [Related]
28. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425 [TBL] [Abstract][Full Text] [Related]
29. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109 [TBL] [Abstract][Full Text] [Related]
30. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Jabbour E; Kantarjian H Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758 [TBL] [Abstract][Full Text] [Related]
32. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia. Huang R; Kang Q; Liu H; Li Y Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311 [TBL] [Abstract][Full Text] [Related]
33. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells. Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Yang K; Fu LW Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000 [TBL] [Abstract][Full Text] [Related]
36. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]. Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D; Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136 [TBL] [Abstract][Full Text] [Related]
37. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389 [TBL] [Abstract][Full Text] [Related]
38. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Danisz K; Blasiak J Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759 [TBL] [Abstract][Full Text] [Related]
39. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia. Vysochinskaya V; Dovbysh O; Gorshkov A; Brodskaia A; Dubina M; Vasin A; Zabrodskaya Y Biomolecules; 2024 May; 14(6):. PubMed ID: 38927048 [TBL] [Abstract][Full Text] [Related]